These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37378674)

  • 1. Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.
    Liu H; Sun L; Lian J; Wang L; Xi Y; Zhao G; Wang J; Lan X; Du H; Yan W; Bu P; Wang P; Moore A; Zhao H
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11397-11410. PubMed ID: 37378674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
    Özcan D; Lade-Keller J; Tramm T
    Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
    Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
    Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
    Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
    Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
    Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
    Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of DNA mismatch repair proteins in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
    Okadome K; Baba Y; Yasuda-Yoshihara N; Nomoto D; Yagi T; Toihata T; Ogawa K; Sawayama H; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
    Cancer Sci; 2022 Feb; 113(2):399-410. PubMed ID: 34773342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Programmed Cell Death-L1 (PD-L1) Protein and Mismatch Repair Mutations in Orbital Tumours-a Pilot Study.
    AlSemari MA; Strianese D; Abu Safieh L; Al Hussain H; Abedalthagafi M; Edward DP
    Eur J Ophthalmol; 2022 Sep; 32(5):3097-3102. PubMed ID: 34931541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
    Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
    Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.
    Qiao PP; Tian KS; Han LT; Ma B; Shen CK; Zhao RY; Zhang Y; Wei WJ; Chen XP
    Endocrine; 2022 Jun; 76(3):660-670. PubMed ID: 35366156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
    Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
    Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
    Hou Y; Nitta H; Parwani AV; Li Z
    Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
    Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
    Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
    Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
    BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.
    Çakır E; Saygın İ; Ercin ME
    Turk J Med Sci; 2021 Aug; 51(4):1800-1808. PubMed ID: 33600097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
    Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
    Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.